Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
Disc Medicine, Inc. (IRON)
Company Research
Source: GlobeNewswire
WATERTOWN, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to DISC-0974 for the treatment of patients with non-dialysis dependent chronic kidney disease (NDD-CKD) and anemia. “Receiving Fast Track designation highlights the unmet need for the millions of NDD-CKD patients with anemia, as well as the potential of DISC-0974 to address this need,” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc. “We believe DISC-0974 could be a transformative therapy for these patients and are excited to share additional results from our ongoing Phase 1b/2 study in NDD-CKD patients with anemia this year.” Fast Track is a process designed by the FDA to facilita
Show less
Read more
Impact Snapshot
Event Time:
IRON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IRON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IRON alerts
High impacting Disc Medicine, Inc. news events
Weekly update
A roundup of the hottest topics
IRON
News
- Disc Medicine, Inc. (NASDAQ: IRON) had its price target raised by analysts at Stifel Nicolaus from $71.00 to $73.00. They now have a "buy" rating on the stock.MarketBeat
- Disc Medicine, Inc. (NASDAQ: IRON) had its price target lowered by analysts at Morgan Stanley from $75.00 to $40.00. They now have an "equal weight" rating on the stock.MarketBeat
- Disc Medicine, Inc. (NASDAQ: IRON) had its price target lowered by analysts at BMO Capital Markets from $80.00 to $50.00. They now have an "outperform" rating on the stock.MarketBeat
- Disc Medicine, Inc. (NASDAQ: IRON) had its price target lowered by analysts at Stifel Nicolaus from $104.00 to $71.00. They now have a "buy" rating on the stock.MarketBeat
- Attention Disc Medicine, Inc. Investors: Company Investigated by the Portnoy Law FirmGlobeNewswire
IRON
Earnings
- 11/9/23 - Beat
IRON
Sec Filings
- 5/1/24 - Form DEF
- 5/1/24 - Form ARS
- 5/1/24 - Form DEFA14A
- IRON's page on the SEC website